
|Videos|June 7, 2013
Using Selumetinib in Advanced Uveal Melanoma
Author(s)Richard D. Carvajal, MD
Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the use of selumetinib in patients with advanced uveal melanoma.
Advertisement
Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the use of selumetinib in patients with advanced uveal melanoma.
Clinical Pearls
The trial exploring selumetinib was the first ever to find an agent that demonstrated efficacy for patients with advanced uveal melanoma. Even though trametinib (another MEK inhibitor) was recently approved, Carvajal says that clinical trials are still the most appropriate area for treatment with MEK inhibitors in uveal melanoma.
- The trial exploring selumetinib was the first ever to find an agent that demonstrated efficacy for patients with advanced uveal melanoma
- Clinical trials are still the most appropriate area for treatment with MEK inhibitors in this disease type
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































